Gilead drug effectively protects against HIV infection $GILD (+0,8 %)
A six-monthly vaccination with the drug lenacapavir effectively protects against HIV infection.
This is confirmed by data from the pivotal Phase 3 study "Purpose 2", which is presented in the "New England Journal of Medicine" ("NEJM"). Astrid Berner-Rodoreda from Heidelberg University Hospital praised lenacapavir as a real breakthrough.
As a depot injection, lenacapavir provides long-term protection against HIV infection, with a booster scheduled every six months - previously used drugs for HIV pre-exposure prophylaxis (PrEP) such as Truvada must be taken daily as a tablet. Getting vaccinated twice a year is much more convenient than having to remember to take a tablet every day, said Berner-Rodoreda.
